JP2006517572A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006517572A5 JP2006517572A5 JP2006502254A JP2006502254A JP2006517572A5 JP 2006517572 A5 JP2006517572 A5 JP 2006517572A5 JP 2006502254 A JP2006502254 A JP 2006502254A JP 2006502254 A JP2006502254 A JP 2006502254A JP 2006517572 A5 JP2006517572 A5 JP 2006517572A5
- Authority
- JP
- Japan
- Prior art keywords
- phenyl
- isoxazole
- dihydroxy
- carboxylic acid
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 C 1 -C 6 alkyl Chemical group 0.000 claims 57
- 150000001875 compounds Chemical class 0.000 claims 48
- 125000005392 carboxamide group Chemical group NC(=O)* 0.000 claims 16
- 229910052739 hydrogen Inorganic materials 0.000 claims 16
- 239000001257 hydrogen Substances 0.000 claims 16
- 125000001424 substituent group Chemical group 0.000 claims 14
- 125000000623 heterocyclic group Chemical group 0.000 claims 12
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 10
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 10
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 10
- 239000012453 solvate Substances 0.000 claims 10
- 101710113864 Heat shock protein 90 Proteins 0.000 claims 8
- 102100034051 Heat shock protein HSP 90-alpha Human genes 0.000 claims 8
- 125000001246 bromo group Chemical group Br* 0.000 claims 8
- 125000002837 carbocyclic group Chemical group 0.000 claims 8
- 229910052799 carbon Inorganic materials 0.000 claims 8
- 125000001309 chloro group Chemical group Cl* 0.000 claims 8
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 8
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 8
- 229910052757 nitrogen Inorganic materials 0.000 claims 8
- 230000000694 effects Effects 0.000 claims 7
- 150000001204 N-oxides Chemical class 0.000 claims 6
- 125000003277 amino group Chemical group 0.000 claims 6
- 230000001419 dependent effect Effects 0.000 claims 6
- 230000002401 inhibitory effect Effects 0.000 claims 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 6
- 125000002757 morpholinyl group Chemical group 0.000 claims 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 6
- 125000004193 piperazinyl group Chemical group 0.000 claims 6
- 125000003386 piperidinyl group Chemical group 0.000 claims 6
- 239000000651 prodrug Substances 0.000 claims 6
- 229940002612 prodrug Drugs 0.000 claims 6
- 230000003381 solubilizing effect Effects 0.000 claims 6
- 125000004122 cyclic group Chemical group 0.000 claims 5
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 125000006260 ethylaminocarbonyl group Chemical group [H]N(C(*)=O)C([H])([H])C([H])([H])[H] 0.000 claims 4
- 125000001072 heteroaryl group Chemical group 0.000 claims 4
- 150000002431 hydrogen Chemical class 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 4
- 125000004076 pyridyl group Chemical group 0.000 claims 4
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 4
- 125000003107 substituted aryl group Chemical group 0.000 claims 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 4
- 125000004450 alkenylene group Chemical group 0.000 claims 3
- 125000003118 aryl group Chemical group 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 125000006239 protecting group Chemical group 0.000 claims 3
- 125000006727 (C1-C6) alkenyl group Chemical group 0.000 claims 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 2
- 125000006728 (C1-C6) alkynyl group Chemical group 0.000 claims 2
- ILFIRBGRMCGNOO-UHFFFAOYSA-N 1,1-bis($l^{1}-oxidanyl)ethene Chemical group [O]C([O])=C ILFIRBGRMCGNOO-UHFFFAOYSA-N 0.000 claims 2
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 claims 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims 2
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 2
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims 2
- LURPCKMCPZKVLG-UHFFFAOYSA-N 3-(5-chloro-2,4-dihydroxyphenyl)-N-ethyl-4-[4-(morpholin-4-ylmethyl)phenyl]-1,2-oxazole-5-carboxamide Chemical compound CCNC(=O)C=1ON=C(C=2C(=CC(O)=C(Cl)C=2)O)C=1C(C=C1)=CC=C1CN1CCOCC1 LURPCKMCPZKVLG-UHFFFAOYSA-N 0.000 claims 2
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 claims 2
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 2
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 claims 2
- XWAKANMSVGJPQD-UHFFFAOYSA-N 4-[4-(diethylaminomethyl)phenyl]-5-[2,4-dihydroxy-5-(2-methylphenyl)phenyl]-N-ethyl-1,2-oxazole-3-carboxamide Chemical compound CCNC(=O)C1=NOC(C=2C(=CC(O)=C(C=2)C=2C(=CC=CC=2)C)O)=C1C1=CC=C(CN(CC)CC)C=C1 XWAKANMSVGJPQD-UHFFFAOYSA-N 0.000 claims 2
- NSVZNIOGSFQMSQ-UHFFFAOYSA-N 4-[4-(diethylaminomethyl)phenyl]-N-ethyl-5-[5-(4-fluorophenyl)-2,4-dihydroxyphenyl]-1,2-oxazole-3-carboxamide Chemical compound CCNC(=O)C1=NOC(C=2C(=CC(O)=C(C=2)C=2C=CC(F)=CC=2)O)=C1C1=CC=C(CN(CC)CC)C=C1 NSVZNIOGSFQMSQ-UHFFFAOYSA-N 0.000 claims 2
- WNCGSWNZVHEESS-UHFFFAOYSA-N 4-[4-[(cyclohexylamino)methyl]phenyl]-5-(2,4-dihydroxy-5-propan-2-ylphenyl)-N-ethyl-1,2-oxazole-3-carboxamide Chemical compound CCNC(=O)C1=NOC(C=2C(=CC(O)=C(C(C)C)C=2)O)=C1C(C=C1)=CC=C1CNC1CCCCC1 WNCGSWNZVHEESS-UHFFFAOYSA-N 0.000 claims 2
- INSHMVKUWUOWCX-UHFFFAOYSA-N 4-[4-[(tert-butylamino)methyl]phenyl]-5-(2,4-dihydroxy-5-propan-2-ylphenyl)-N-ethyl-1,2-oxazole-3-carboxamide Chemical compound CCNC(=O)C1=NOC(C=2C(=CC(O)=C(C(C)C)C=2)O)=C1C1=CC=C(CNC(C)(C)C)C=C1 INSHMVKUWUOWCX-UHFFFAOYSA-N 0.000 claims 2
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 2
- OVJLXNJAQKKVCO-UHFFFAOYSA-N 5-(2,4-dihydroxy-5-propan-2-ylphenyl)-4-[4-(morpholin-4-ylmethyl)phenyl]-N-propan-2-yl-1,2-oxazole-3-carboxamide Chemical compound CC(C)NC(=O)C1=NOC(C=2C(=CC(O)=C(C(C)C)C=2)O)=C1C(C=C1)=CC=C1CN1CCOCC1 OVJLXNJAQKKVCO-UHFFFAOYSA-N 0.000 claims 2
- RQRUBPKAYFDPFF-UHFFFAOYSA-N 5-(2,4-dihydroxy-5-propan-2-ylphenyl)-4-[4-[(4-methylpiperazin-1-yl)methyl]phenyl]-N-propan-2-yl-1,2-oxazole-3-carboxamide Chemical compound CC(C)NC(=O)C1=NOC(C=2C(=CC(O)=C(C(C)C)C=2)O)=C1C(C=C1)=CC=C1CN1CCN(C)CC1 RQRUBPKAYFDPFF-UHFFFAOYSA-N 0.000 claims 2
- PCXWAYHFMKPLQV-UHFFFAOYSA-N 5-(2,4-dihydroxy-5-propan-2-ylphenyl)-N-ethyl-4-[4-(ethylaminomethyl)phenyl]-1,2-oxazole-3-carboxamide Chemical compound C1=CC(CNCC)=CC=C1C1=C(C=2C(=CC(O)=C(C(C)C)C=2)O)ON=C1C(=O)NCC PCXWAYHFMKPLQV-UHFFFAOYSA-N 0.000 claims 2
- KIPRUYSELCZZTP-UHFFFAOYSA-N 5-(2,4-dihydroxy-5-propan-2-ylphenyl)-N-ethyl-4-[4-[(2-methoxyethylamino)methyl]phenyl]-1,2-oxazole-3-carboxamide Chemical compound CCNC(=O)C1=NOC(C=2C(=CC(O)=C(C(C)C)C=2)O)=C1C1=CC=C(CNCCOC)C=C1 KIPRUYSELCZZTP-UHFFFAOYSA-N 0.000 claims 2
- LRQGHEGCJYDULB-UHFFFAOYSA-N 5-(2,4-dihydroxy-5-propan-2-ylphenyl)-N-ethyl-4-[4-[(4-methylpiperazin-1-yl)methyl]phenyl]-1,2-oxazole-3-carboxamide Chemical compound CCNC(=O)C1=NOC(C=2C(=CC(O)=C(C(C)C)C=2)O)=C1C(C=C1)=CC=C1CN1CCN(C)CC1 LRQGHEGCJYDULB-UHFFFAOYSA-N 0.000 claims 2
- FWXKZIWZSRANCX-UHFFFAOYSA-N 5-(2,4-dihydroxy-5-propan-2-ylphenyl)-N-ethyl-4-[4-[(propan-2-ylamino)methyl]phenyl]-1,2-oxazole-3-carboxamide Chemical compound CCNC(=O)C1=NOC(C=2C(=CC(O)=C(C(C)C)C=2)O)=C1C1=CC=C(CNC(C)C)C=C1 FWXKZIWZSRANCX-UHFFFAOYSA-N 0.000 claims 2
- KZJAWYUJSFALRK-UHFFFAOYSA-N 5-(5-chloro-2,4-dihydroxyphenyl)-4-[4-(piperidin-1-ylmethyl)phenyl]-N-propan-2-yl-1,2-oxazole-3-carboxamide Chemical compound CC(C)NC(=O)C1=NOC(C=2C(=CC(O)=C(Cl)C=2)O)=C1C(C=C1)=CC=C1CN1CCCCC1 KZJAWYUJSFALRK-UHFFFAOYSA-N 0.000 claims 2
- APGOABVITLQCKW-UHFFFAOYSA-N 5-(5-chloro-2,4-dihydroxyphenyl)-n-ethyl-4-[4-(morpholin-4-ylmethyl)phenyl]isoxazole-3-carboxamide Chemical compound CCNC(=O)C1=NOC(C=2C(=CC(O)=C(Cl)C=2)O)=C1C(C=C1)=CC=C1CN1CCOCC1 APGOABVITLQCKW-UHFFFAOYSA-N 0.000 claims 2
- WDORNDZICKCYOH-UHFFFAOYSA-N 5-(5-tert-butyl-2,4-dihydroxyphenyl)-4-[4-(diethylaminomethyl)phenyl]-N-ethyl-1,2-oxazole-3-carboxamide Chemical compound CCNC(=O)C1=NOC(C=2C(=CC(O)=C(C=2)C(C)(C)C)O)=C1C1=CC=C(CN(CC)CC)C=C1 WDORNDZICKCYOH-UHFFFAOYSA-N 0.000 claims 2
- ZTLWCZRCEYWCOR-UHFFFAOYSA-N 5-(5-tert-butyl-2,4-dihydroxyphenyl)-N-ethyl-4-[4-[(4-methylpiperazin-1-yl)methyl]phenyl]-1,2-oxazole-3-carboxamide Chemical compound CCNC(=O)C1=NOC(C=2C(=CC(O)=C(C=2)C(C)(C)C)O)=C1C(C=C1)=CC=C1CN1CCN(C)CC1 ZTLWCZRCEYWCOR-UHFFFAOYSA-N 0.000 claims 2
- IAFDYDGLYZZMSJ-UHFFFAOYSA-N 5-[2,4-dihydroxy-5-(2-methylpropyl)phenyl]-N-ethyl-4-[4-(piperidin-1-ylmethyl)phenyl]-1,2-oxazole-3-carboxamide Chemical compound CCNC(=O)C1=NOC(C=2C(=CC(O)=C(CC(C)C)C=2)O)=C1C(C=C1)=CC=C1CN1CCCCC1 IAFDYDGLYZZMSJ-UHFFFAOYSA-N 0.000 claims 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 2
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- NAIOWGXKMUYTEJ-UHFFFAOYSA-N N-ethyl-5-(5-ethyl-2,4-dihydroxyphenyl)-4-[4-[(4-methylpiperazin-1-yl)methyl]phenyl]-1,2-oxazole-3-carboxamide Chemical compound CCNC(=O)C1=NOC(C=2C(=CC(O)=C(CC)C=2)O)=C1C(C=C1)=CC=C1CN1CCN(C)CC1 NAIOWGXKMUYTEJ-UHFFFAOYSA-N 0.000 claims 2
- KOEWQOUBZIGXIF-UHFFFAOYSA-N N-ethyl-5-[5-(2-fluorophenyl)-2,4-dihydroxyphenyl]-4-[4-(pyrrolidin-1-ylmethyl)phenyl]-1,2-oxazole-3-carboxamide Chemical compound CCNC(=O)C1=NOC(C=2C(=CC(O)=C(C=2)C=2C(=CC=CC=2)F)O)=C1C(C=C1)=CC=C1CN1CCCC1 KOEWQOUBZIGXIF-UHFFFAOYSA-N 0.000 claims 2
- 125000002947 alkylene group Chemical group 0.000 claims 2
- 125000004419 alkynylene group Chemical group 0.000 claims 2
- 150000001721 carbon Chemical group 0.000 claims 2
- KVALWNOGXNZJNM-UHFFFAOYSA-N chembl252165 Chemical compound CCNC(=O)C1=NOC(C=2C(=CC(O)=C(C(C)C)C=2)O)=C1C1=CC=C(CN(CC)CC)C=C1 KVALWNOGXNZJNM-UHFFFAOYSA-N 0.000 claims 2
- FQKHRMZPORXQSR-UHFFFAOYSA-N chembl252370 Chemical compound CCNC(=O)C1=NOC(C=2C(=CC(O)=C(C(C)C)C=2)O)=C1C(C=C1)=CC=C1CN1CCCCC1 FQKHRMZPORXQSR-UHFFFAOYSA-N 0.000 claims 2
- COBVQNNJVURGON-UHFFFAOYSA-N chembl253185 Chemical compound CCNC(=O)C1=NOC(C=2C(=CC(O)=C(C=2)C(C)(C)C)O)=C1C(C=C1)=CC=C1CN1CCCCC1 COBVQNNJVURGON-UHFFFAOYSA-N 0.000 claims 2
- AEZSTVRHWTURDU-UHFFFAOYSA-N chembl253399 Chemical compound CCNC(=O)C1=NOC(C=2C(=CC(O)=C(Cl)C=2)O)=C1C1=CC=C(CN(CC)CC)C=C1 AEZSTVRHWTURDU-UHFFFAOYSA-N 0.000 claims 2
- NBORIEUQDSFVFQ-UHFFFAOYSA-N chembl253836 Chemical compound CCNC(=O)C1=NOC(C=2C(=CC(O)=C(CCC=3C=CC=CC=3)C=2)O)=C1C(C=C1)=CC=C1CN1CCOCC1 NBORIEUQDSFVFQ-UHFFFAOYSA-N 0.000 claims 2
- LALDVGOZMSLLOR-UHFFFAOYSA-N chembl253837 Chemical compound CCNC(=O)C1=NOC(C=2C(=CC(O)=C(CC)C=2)O)=C1C1=CC=C(CN(CC)CC)C=C1 LALDVGOZMSLLOR-UHFFFAOYSA-N 0.000 claims 2
- IFYJCWYDVYZPLI-UHFFFAOYSA-N chembl254248 Chemical compound CCNC(=O)C1=NOC(C=2C(=CC(O)=C(C=2)C=2C=CC=CC=2)O)=C1C(C=C1)=CC=C1CN1CCOCC1 IFYJCWYDVYZPLI-UHFFFAOYSA-N 0.000 claims 2
- GVNFOZYVKKSCJY-UHFFFAOYSA-N chembl254458 Chemical compound CCNC(=O)C1=NOC(C=2C(=CC(O)=C(CC(C)C)C=2)O)=C1C(C=C1)=CC=C1CN1CCOCC1 GVNFOZYVKKSCJY-UHFFFAOYSA-N 0.000 claims 2
- WLYWTGDTMWWNNG-UHFFFAOYSA-N chembl399583 Chemical compound CCNC(=O)C1=NOC(C=2C(=CC(O)=C(C=2)C(C)(C)C)O)=C1C(C=C1)=CC=C1CN1CCOCC1 WLYWTGDTMWWNNG-UHFFFAOYSA-N 0.000 claims 2
- RNLVKRYMKWCANV-UHFFFAOYSA-N chembl400187 Chemical compound CCNC(=O)C1=NOC(C=2C(=CC(O)=C(CC)C=2)O)=C1C(C=C1)=CC=C1CN1CCOCC1 RNLVKRYMKWCANV-UHFFFAOYSA-N 0.000 claims 2
- YAYJACNPYWHUDS-UHFFFAOYSA-N chembl401370 Chemical compound CCNC(=O)C1=NOC(C=2C(=CC(O)=C(C=2)C=2C=CC=CC=2)O)=C1C1=CC=C(CN(CC)CC)C=C1 YAYJACNPYWHUDS-UHFFFAOYSA-N 0.000 claims 2
- RUXXRSDEOCYOTM-UHFFFAOYSA-N chembl427716 Chemical compound CCNC(=O)C1=NOC(C=2C(=CC(O)=C(Cl)C=2)O)=C1C(C=C1)=CC=C1CN1CCN(C)CC1 RUXXRSDEOCYOTM-UHFFFAOYSA-N 0.000 claims 2
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 2
- 125000001153 fluoro group Chemical group F* 0.000 claims 2
- 125000002541 furyl group Chemical group 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 150000004677 hydrates Chemical class 0.000 claims 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 2
- NDAZATDQFDPQBD-UHFFFAOYSA-N luminespib Chemical compound CCNC(=O)C1=NOC(C=2C(=CC(O)=C(C(C)C)C=2)O)=C1C(C=C1)=CC=C1CN1CCOCC1 NDAZATDQFDPQBD-UHFFFAOYSA-N 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 2
- SOWBFZRMHSNYGE-UHFFFAOYSA-N oxamic acid Chemical compound NC(=O)C(O)=O SOWBFZRMHSNYGE-UHFFFAOYSA-N 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 239000002504 physiological saline solution Substances 0.000 claims 2
- 239000000243 solution Substances 0.000 claims 2
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 2
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 239000000725 suspension Substances 0.000 claims 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 2
- 125000000335 thiazolyl group Chemical group 0.000 claims 2
- 125000001544 thienyl group Chemical group 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 101100507655 Canis lupus familiaris HSPA1 gene Proteins 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 206010021143 Hypoxia Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 125000005195 alkyl amino carbonyloxy group Chemical group 0.000 claims 1
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000004696 endometrium Anatomy 0.000 claims 1
- 201000011066 hemangioma Diseases 0.000 claims 1
- 125000004464 hydroxyphenyl group Chemical group 0.000 claims 1
- 230000007954 hypoxia Effects 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 230000000302 ischemic effect Effects 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 208000008864 scrapie Diseases 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
- 0 **c1n[o]c(I)c1* Chemical compound **c1n[o]c(I)c1* 0.000 description 3
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0303105A GB0303105D0 (en) | 2003-02-11 | 2003-02-11 | Isoxazole compounds |
| GB0303105.1 | 2003-02-11 | ||
| GBGB0306560.4A GB0306560D0 (en) | 2003-03-21 | 2003-03-21 | Isoxazole compounds |
| GB0306560.4 | 2003-03-21 | ||
| GB0313751.0 | 2003-06-13 | ||
| GB0313751A GB0313751D0 (en) | 2003-06-13 | 2003-06-13 | Isoxazole compounds |
| PCT/GB2004/000506 WO2004072051A1 (en) | 2003-02-11 | 2004-02-09 | Isoxazole compounds as inhibitors of heat shock proteins |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006517572A JP2006517572A (ja) | 2006-07-27 |
| JP2006517572A5 true JP2006517572A5 (https=) | 2007-05-10 |
| JP4921162B2 JP4921162B2 (ja) | 2012-04-25 |
Family
ID=32872455
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006502254A Expired - Lifetime JP4921162B2 (ja) | 2003-02-11 | 2004-02-09 | 熱ショックタンパク質の阻害剤としてのイソオキサゾール化合物類 |
Country Status (18)
| Country | Link |
|---|---|
| US (6) | US7705027B2 (https=) |
| EP (1) | EP1611112B1 (https=) |
| JP (1) | JP4921162B2 (https=) |
| KR (1) | KR101166749B1 (https=) |
| CN (1) | CN1771235B (https=) |
| AU (1) | AU2004210779B2 (https=) |
| BR (1) | BRPI0407403B1 (https=) |
| CA (1) | CA2515726C (https=) |
| CY (1) | CY1113761T1 (https=) |
| DK (1) | DK1611112T3 (https=) |
| EA (1) | EA009919B1 (https=) |
| ES (1) | ES2393483T3 (https=) |
| MX (1) | MXPA05008335A (https=) |
| NO (1) | NO335001B1 (https=) |
| NZ (1) | NZ541479A (https=) |
| PT (1) | PT1611112E (https=) |
| SI (1) | SI1611112T1 (https=) |
| WO (1) | WO2004072051A1 (https=) |
Families Citing this family (115)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI297335B (en) | 2001-07-10 | 2008-06-01 | Synta Pharmaceuticals Corp | Taxol enhancer compounds |
| TWI332943B (en) | 2001-07-10 | 2010-11-11 | Synta Pharmaceuticals Corp | Taxol enhancer compounds |
| TWI252847B (en) | 2001-07-10 | 2006-04-11 | Synta Pharmaceuticals Corp | Synthesis of taxol enhancers |
| TWI330079B (en) | 2003-01-15 | 2010-09-11 | Synta Pharmaceuticals Corp | Treatment for cancers |
| EA009919B1 (ru) | 2003-02-11 | 2008-04-28 | Вернэлис (Кембридж) Лимитед | Соединения изоксазола |
| GB0315111D0 (en) * | 2003-06-27 | 2003-07-30 | Cancer Rec Tech Ltd | Substituted 5-membered ring compounds and their use |
| JPWO2005063222A1 (ja) * | 2003-12-26 | 2007-07-19 | 協和醗酵工業株式会社 | Ｈｓｐ９０ファミリー蛋白質阻害剤 |
| ATE538778T1 (de) | 2004-05-28 | 2012-01-15 | Unigen Inc | 1-(3-methyl-2,4-dimethoxyphenyl)-3-(2',4'- dihydroxyphenyl)-propan als hochwirksamer tyrosinase-inhibitor |
| GB0412769D0 (en) | 2004-06-08 | 2004-07-07 | Novartis Ag | Organic compounds |
| CN1993318B (zh) | 2004-06-23 | 2012-10-03 | Synta医药公司 | 用于治疗癌症的双（硫代-酰肼酰胺）盐 |
| JP4820758B2 (ja) | 2004-09-22 | 2011-11-24 | 日本化薬株式会社 | 新規ブロック共重合体、ミセル調製物及びそれを有効成分とする抗癌剤 |
| JPWO2006051808A1 (ja) | 2004-11-09 | 2008-05-29 | 協和醗酵工業株式会社 | Ｈｓｐ９０ファミリー蛋白質阻害剤 |
| WO2006055760A1 (en) | 2004-11-18 | 2006-05-26 | Synta Pharmaceuticals Corp. | Triazole compounds that modulate hsp90 activity |
| DE102005007304A1 (de) * | 2005-02-17 | 2006-08-24 | Merck Patent Gmbh | Triazolderivate |
| NZ560712A (en) * | 2005-02-17 | 2010-12-24 | Synta Pharmaceuticals Corp | (3,4,5-trisubstituted-phenyl)isoxazole combretastin derivatives for the treatment of disorders |
| FR2882361A1 (fr) * | 2005-02-22 | 2006-08-25 | Aventis Pharma Sa | Nouveaux derives de 3-aryl-1,2-benzisoxazole, compositions les contenant et leur utilisation |
| JP4956737B2 (ja) * | 2005-02-23 | 2012-06-20 | 国立大学法人名古屋大学 | 抗ポリグルタミン病剤 |
| US8399464B2 (en) | 2005-03-09 | 2013-03-19 | Nippon Kayaku Kabushiki Kaisha | HSP90 inhibitor |
| CN1834095B (zh) * | 2005-03-18 | 2011-04-20 | 中国科学院上海药物研究所 | 一类非核苷类抗病毒抑制剂及其制备方法和用途 |
| JP2008137894A (ja) * | 2005-03-22 | 2008-06-19 | Nippon Kayaku Co Ltd | 新規なアセチレン誘導体 |
| FR2884252B1 (fr) | 2005-04-08 | 2007-05-18 | Aventis Pharma Sa | Nouveaux derives d'isoindoles, compositions les contenant, leur preparation et leurs utilisations pharmaceutiques notamment en tant qu'inhibiteurs d'activites de la proteine chaperone hsp90 |
| KR101411167B1 (ko) | 2005-04-13 | 2014-06-23 | 아스텍스 테라퓨틱스 리미티드 | 하이드록시벤즈아미드 유도체 및 ｈｓｐ90 억제제로서의이의 용도 |
| WO2006113695A1 (en) | 2005-04-15 | 2006-10-26 | Synta Pharmaceuticals Corp. | Combination cancer therapy with bis(thiohydrazide) amide compounds |
| FR2885904B1 (fr) | 2005-05-19 | 2007-07-06 | Aventis Pharma Sa | Nouveaux derives du fluorene, compositions les contenant et utilisation |
| WO2006126751A1 (en) * | 2005-05-25 | 2006-11-30 | Korea Research Institute Of Bioscience And Biotechnology | New diaryl-isoxazole derivatives, and pharmaceutical compositions containing the same for the prevention and the treatment of cancers |
| WO2007094819A2 (en) | 2005-08-18 | 2007-08-23 | Synta Pharmaceuticals Corp. | Triazole compounds that modulate hsp90 activity |
| GB0603880D0 (en) * | 2006-02-27 | 2006-04-05 | Novartis Ag | Organic compounds |
| US7754725B2 (en) | 2006-03-01 | 2010-07-13 | Astex Therapeutics Ltd. | Dihydroxyphenyl isoindolymethanones |
| JP5249016B2 (ja) | 2006-03-28 | 2013-07-31 | 日本化薬株式会社 | タキサン類の高分子結合体 |
| WO2007131034A1 (en) * | 2006-05-03 | 2007-11-15 | The Regents Of The University Of Michigan | Pyrimidone derivatives which are modulators of heat shock protein (hsp) 70 |
| KR20090009241A (ko) | 2006-05-18 | 2009-01-22 | 니폰 가야꾸 가부시끼가이샤 | 포도필로톡신류의 고분자 결합체 |
| TWI440632B (zh) | 2006-08-21 | 2014-06-11 | Synta Pharmaceuticals Corp | 用於治療增生性疾病的化合物 |
| JP2010502616A (ja) | 2006-08-31 | 2010-01-28 | シンタ ファーマシューティカルズ コーポレーション | 癌を治療するためのビス（チオヒドラジドアミド）の組み合わせ |
| AU2007294752A1 (en) * | 2006-09-14 | 2008-03-20 | Synta Pharmaceuticals Corp. | Compounds for the treatment of angiogenesis |
| ES2584840T3 (es) * | 2006-10-03 | 2016-09-29 | Nippon Kayaku Kabushiki Kaisha | Compuesto de un derivado de resorcinol con un polímero |
| JP5528807B2 (ja) | 2006-10-12 | 2014-06-25 | アステックス、セラピューティックス、リミテッド | 複合薬剤 |
| GB0620259D0 (en) | 2006-10-12 | 2006-11-22 | Astex Therapeutics Ltd | Pharmaceutical compounds |
| EP2073802A1 (en) | 2006-10-12 | 2009-07-01 | Astex Therapeutics Limited | Pharmaceutical combinations |
| JP5518478B2 (ja) | 2006-10-12 | 2014-06-11 | アステックス、セラピューティックス、リミテッド | 医薬化合物 |
| WO2008044041A1 (en) | 2006-10-12 | 2008-04-17 | Astex Therapeutics Limited | Pharmaceutical combinations |
| JP5410285B2 (ja) | 2006-10-12 | 2014-02-05 | アステックス、セラピューティックス、リミテッド | 医薬化合物 |
| WO2008056596A1 (fr) | 2006-11-06 | 2008-05-15 | Nippon Kayaku Kabushiki Kaisha | Dérivé polymère d'un antagoniste métabolique d'acide nucléique |
| JP5548365B2 (ja) | 2006-11-08 | 2014-07-16 | 日本化薬株式会社 | 核酸系代謝拮抗剤の高分子誘導体 |
| US7799954B2 (en) | 2006-11-17 | 2010-09-21 | Abraxis Bioscience, Llc | Dicarbonyl derivatives and methods of use |
| CN101636162A (zh) * | 2007-03-01 | 2010-01-27 | 诺瓦提斯公司 | 5-(2,4-二羟基-5-异丙基-苯基)-4-(4-吗啉-4-基甲基-苯基)-异唑-3-甲酸乙基酰胺的酸加成盐、水合物和多晶型物以及包含这些形式的制剂 |
| EP2183237A1 (en) | 2007-07-25 | 2010-05-12 | F. Hoffmann-Roche AG | Benzofuran- and benzo[b]thiophene-2-carboxylic acid amide derivatives and use thereof as histamine 3 receptor modulators |
| AU2008293542B9 (en) | 2007-08-27 | 2014-08-07 | Dart Neuroscience (Cayman) Ltd. | Therapeutic isoxazole compounds |
| WO2009026658A1 (en) * | 2007-08-29 | 2009-03-05 | The University Of Sydney | Ppar agonists |
| US8703878B2 (en) | 2007-09-28 | 2014-04-22 | Nippon Kayaku Kabushiki Kaisha | High-molecular weight conjugate of steroids |
| US7932279B2 (en) | 2007-10-12 | 2011-04-26 | Arqule, Inc. | Substituted tetrazole compounds and uses thereof |
| TW200922595A (en) * | 2007-10-12 | 2009-06-01 | Novartis Ag | Organic compounds |
| BRPI0817897A2 (pt) * | 2007-11-02 | 2019-09-24 | Methylgene Inc | composto, composição, e, métodos de inibição da atividade hdac, e de tratamento de uma doença responsiva a um inibidor de atividade hdac |
| GB0722680D0 (en) * | 2007-11-19 | 2007-12-27 | Topotarget As | Therapeutic compounds and their use |
| WO2009116509A1 (ja) | 2008-03-18 | 2009-09-24 | 日本化薬株式会社 | 生理活性物質の高分子結合体 |
| GB0806527D0 (en) | 2008-04-11 | 2008-05-14 | Astex Therapeutics Ltd | Pharmaceutical compounds |
| LT5623B (lt) * | 2008-04-30 | 2010-01-25 | Biotechnologijos Institutas, , | 5-aril-4-(5-pakeistieji 2,4-dihidroksifenil)-1,2,3-tiadiazolai kaip hsp90 šaperono slopikliai ir tarpiniai junginiai jiems gauti |
| WO2009136572A1 (ja) | 2008-05-08 | 2009-11-12 | 日本化薬株式会社 | 葉酸若しくは葉酸誘導体の高分子結合体 |
| US20110124634A1 (en) * | 2008-05-13 | 2011-05-26 | Poniard Pharmaceuticals, Inc. | Bioactive compounds for treatment of cancer and neurodegenerative diseases |
| TWI450898B (zh) * | 2008-07-04 | 2014-09-01 | Sigma Tau Res Switzerland Sa | 具有抗腫瘤活性之芳基異唑化合物 |
| CA2730265C (en) * | 2008-07-21 | 2016-06-28 | Unigen, Inc. | Series of skin-whitening (lightening) compounds |
| CN105727297A (zh) * | 2008-11-28 | 2016-07-06 | 诺华股份有限公司 | 包含hsp90抑制剂和mtor抑制剂的药物组合 |
| MA32933B1 (fr) * | 2008-11-28 | 2012-01-02 | Novartis Ag | Combinaison d'inhibiteurs de hspo90 et d'herceptine |
| WO2010121963A1 (en) | 2009-04-21 | 2010-10-28 | Nerviano Medical Sciences S.R.L. | Resorcinol derivatives as hsp90 inhibitors |
| EP2431403B1 (en) | 2009-05-15 | 2016-09-28 | Nipponkayaku Kabushikikaisha | Polymer conjugate of bioactive substance having hydroxy group |
| US20120283120A1 (en) | 2009-09-29 | 2012-11-08 | Takeda Pharmaceutical Company Limited | Screening method |
| HUE026447T2 (en) | 2009-10-16 | 2016-05-30 | Novartis Ag | Pharmacodynamic tumor response biomarkers |
| CN102753546A (zh) * | 2010-02-17 | 2012-10-24 | 日东制药株式会社 | 新型5-元杂环衍生物及其制备方法 |
| US9205086B2 (en) | 2010-04-19 | 2015-12-08 | Synta Pharmaceuticals Corp. | Cancer therapy using a combination of a Hsp90 inhibitory compounds and a EGFR inhibitor |
| EP2641605B1 (en) | 2010-11-17 | 2018-03-07 | Nippon Kayaku Kabushiki Kaisha | Polymer derivative of cytidine metabolism antagonist |
| AU2012231008B2 (en) | 2011-03-24 | 2017-05-11 | Unigen, Inc. | Compounds and methods for preparation of diarylpropanes |
| WO2013015661A2 (en) * | 2011-07-28 | 2013-01-31 | Ildong Pharm Co.,Ltd. | Novel prodrugs of 5-(2,4-dihydroxy-5-isopropylphenyl)-n-ethyl-4-(5-methyl1-1,2,4-oxadiazol-3-yl)isoxazole-3-carboxamide |
| CN102351655A (zh) * | 2011-08-18 | 2012-02-15 | 杭州澳赛诺化工有限公司 | 一种4-异丙基间苯二酚的合成方法 |
| KR101849142B1 (ko) | 2011-09-11 | 2018-04-16 | 니폰 가야꾸 가부시끼가이샤 | 블록 공중합체의 제조방법 |
| MX2014004559A (es) | 2011-10-14 | 2014-08-01 | Novartis Ag | Derivados de 2-carboxamida cicloamino urea en combinacion con inhibidores de hsp90 para el tratamiento de enfermedades proliferativas. |
| CN103086994A (zh) * | 2011-10-31 | 2013-05-08 | 上海壹志医药科技有限公司 | 异噁唑衍生物的盐 |
| AU2012332424A1 (en) | 2011-11-02 | 2014-06-05 | Synta Pharmaceuticals Corp. | Combination therapy of Hsp90 inhibitors with platinum-containing agents |
| EP2773345A1 (en) | 2011-11-02 | 2014-09-10 | Synta Pharmaceuticals Corp. | Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors |
| WO2013074594A1 (en) | 2011-11-14 | 2013-05-23 | Synta Pharmaceuticals Corp. | Combination therapy of hsp90 inhibitors with braf inhibitors |
| WO2014074580A1 (en) | 2012-11-07 | 2014-05-15 | Novartis Ag | Combination therapy |
| HRP20192020T1 (hr) * | 2012-11-09 | 2020-02-07 | Mmv Medicines For Malaria Venture | Derivati heteroarila i njihova upotreba |
| WO2014074778A1 (en) | 2012-11-09 | 2014-05-15 | Jacobus Pharmaceutical Company, Inc. | Aryl derivatives and uses thereof |
| WO2014141194A2 (en) * | 2013-03-15 | 2014-09-18 | Novartis Ag | Biomarker |
| AU2014302458A1 (en) * | 2013-06-26 | 2015-12-24 | Proteostasis Therapeutics, Inc. | Methods of modulating CFTR activity |
| SG10201900002QA (en) | 2014-01-24 | 2019-02-27 | Dana Farber Cancer Institue Inc | Antibody molecules to pd-1 and uses thereof |
| EP3099717B1 (en) | 2014-01-31 | 2019-03-27 | Novartis AG | Antibody molecules to tim-3 and uses thereof |
| US20150259420A1 (en) | 2014-03-14 | 2015-09-17 | Novartis Ag | Antibody molecules to lag-3 and uses thereof |
| EP3157917B1 (en) * | 2014-06-19 | 2020-03-18 | Proteostasis Therapeutics, Inc. | Compounds, compositions and methods of increasing cftr activity |
| EP3202766B1 (en) * | 2014-10-01 | 2019-12-25 | Daiichi Sankyo Company, Limited | Isoxazole derivative as mutated isocitrate dehydrogenase 1 inhibitor |
| MA41044A (fr) | 2014-10-08 | 2017-08-15 | Novartis Ag | Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer |
| TWI716362B (zh) | 2014-10-14 | 2021-01-21 | 瑞士商諾華公司 | 針對ｐｄ－ｌ１之抗體分子及其用途 |
| WO2016100882A1 (en) | 2014-12-19 | 2016-06-23 | Novartis Ag | Combination therapies |
| CN104725329B (zh) * | 2015-01-13 | 2017-01-18 | 陕西科技大学 | 一种具有抗肿瘤活性的异恶唑羧酸类化合物及其合成方法 |
| JP6760946B2 (ja) * | 2015-01-22 | 2020-09-23 | チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッドChia Tai Tianqing Pharmaceutical Group Co., Ltd. | Ｈｓｐ９０阻害剤としてのレゾルシノール誘導体 |
| HK1248603A1 (zh) | 2015-03-10 | 2018-10-19 | Aduro Biotech, Inc. | 用於活化"干扰素基因的刺激剂"依懒性信号传导的组合物和方法 |
| CN106349180B (zh) * | 2015-07-14 | 2020-05-19 | 上海翰森生物医药科技有限公司 | 4,5-二苯基异噁唑衍生物及其制备方法和应用 |
| DK3317301T3 (da) | 2015-07-29 | 2021-06-28 | Immutep Sas | Kombinationsterapier omfattende antistofmolekyler mod lag-3 |
| EP3878465A1 (en) | 2015-07-29 | 2021-09-15 | Novartis AG | Combination therapies comprising antibody molecules to tim-3 |
| US20180222982A1 (en) | 2015-07-29 | 2018-08-09 | Novartis Ag | Combination therapies comprising antibody molecules to pd-1 |
| EP3370768B9 (en) | 2015-11-03 | 2022-03-16 | Janssen Biotech, Inc. | Antibodies specifically binding pd-1 and their uses |
| WO2017106656A1 (en) | 2015-12-17 | 2017-06-22 | Novartis Ag | Antibody molecules to pd-1 and uses thereof |
| CN107540624B (zh) * | 2016-06-29 | 2020-06-16 | 广州市恒诺康医药科技有限公司 | 热休克蛋白抑制剂及其制备方法和应用 |
| CN108191830B (zh) * | 2016-06-30 | 2019-06-14 | 珠海赛隆药业股份有限公司（长沙）医药研发中心 | 一种富马酸沃诺拉赞中间体ⅳ及其制备方法 |
| WO2018009466A1 (en) | 2016-07-05 | 2018-01-11 | Aduro Biotech, Inc. | Locked nucleic acid cyclic dinucleotide compounds and uses thereof |
| CN109641858B (zh) * | 2016-07-21 | 2021-06-25 | 正大天晴药业集团股份有限公司 | 间苯二酚类衍生物的结晶、盐及其制备方法 |
| UY37695A (es) | 2017-04-28 | 2018-11-30 | Novartis Ag | Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo |
| US12398209B2 (en) | 2018-01-22 | 2025-08-26 | Janssen Biotech, Inc. | Methods of treating cancers with antagonistic anti-PD-1 antibodies |
| CN111217762B (zh) * | 2018-11-23 | 2021-08-20 | 华中师范大学 | 多卤代5-(2-羟基苯基)异噁唑类化合物及其制备方法和应用 |
| US20220362276A1 (en) * | 2019-05-13 | 2022-11-17 | The Trustees Of Princeton University | Small Molecule Inhibitors of Viral Replication |
| CN110283080A (zh) * | 2019-07-05 | 2019-09-27 | 山西大学 | 一种含氟的二苯甲酮衍生物及其制备方法和应用 |
| WO2021152113A1 (en) | 2020-01-31 | 2021-08-05 | Bayer Aktiengesellschaft | Substituted 2,3-benzodiazepines derivatives |
| WO2022075780A1 (ko) * | 2020-10-07 | 2022-04-14 | 광주과학기술원 | 과민성 방광의 예방 또는 치료용 약학적 조성물 |
| CN115160250B (zh) * | 2021-04-02 | 2024-06-04 | 沈阳药科大学 | 4,6-联苯二酚类衍生物及其用途 |
| US11324737B1 (en) * | 2021-05-25 | 2022-05-10 | Louis Habash | Modulating expression level of a gene encoding a heat shock protein by treating a human subject with a nitroxide |
| US11729925B2 (en) | 2021-06-15 | 2023-08-15 | Erico International Corporation | Mounting bracket with angled mounting openings for electrical boxes |
| CN114751870B (zh) * | 2022-02-28 | 2023-10-20 | 贵州医科大学 | 一种2-(异噁唑-5-基)苯基-3,4-二羟基苯甲酸酯及其衍生物及合成方法和应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0418667B1 (de) * | 1989-09-22 | 1995-08-16 | BASF Aktiengesellschaft | Carbonsäureamide |
| WO1992019604A1 (en) * | 1991-05-01 | 1992-11-12 | Taiho Pharmaceutical Co., Ltd. | Novel isoxazole derivative and salt thereof |
| WO1994024095A1 (en) * | 1993-04-16 | 1994-10-27 | Abbott Laboratories | Immunosuppressive agents |
| CZ298022B6 (cs) * | 1996-10-15 | 2007-05-30 | G. D. Searle & Co. | Použití inhibitoru cyklooxygenázy-2 pro výrobu léciva pro lécení a prevenci neoplazie |
| CA2276034A1 (en) * | 1996-12-23 | 1998-07-02 | Mimi Lifen Quan | Oxygen or sulfur containing 5-membered heteroaromatics as factor xa inhibitors |
| US6187797B1 (en) * | 1996-12-23 | 2001-02-13 | Dupont Pharmaceuticals Company | Phenyl-isoxazoles as factor XA Inhibitors |
| EP1102755B1 (en) | 1998-08-07 | 2006-01-04 | Chiron Corporation | Substituted isoxazole derivatives as estrogen receptor modulators |
| ATE246197T1 (de) * | 1998-09-09 | 2003-08-15 | Metabasis Therapeutics Inc | Neue heteroaromatische fructose 1,6- bisphosphatase inhibitoren |
| IL143569A0 (en) * | 1998-12-24 | 2002-04-21 | Metabasis Therapeutics Inc | A combination of fbpase inhibitors and insulin sensitizers for the treatment of diabetes |
| MXPA02001565A (es) * | 1999-08-13 | 2005-07-14 | Vertex Pharma | Inhibidores de cinasas c-jun n-terminal (jnk) y de otras cinasas proteicas. |
| CA2396713A1 (en) * | 1999-12-22 | 2001-07-05 | Metabasis Therapeutics, Inc. | Novel bisamidate phosphonate prodrugs |
| US6673818B2 (en) * | 2001-04-20 | 2004-01-06 | Pharmacia Corporation | Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation |
| JP2002363079A (ja) * | 2001-05-31 | 2002-12-18 | National Cancer Center-Japan | モフェゾラクを有効成分とする、消化管ポリープおよび／または消化管がんの予防または治療のための薬剤 |
| EP1456180B1 (en) * | 2001-12-21 | 2007-10-03 | Vernalis (Cambridge) Limited | 3-(2,4)dihydroxyphenyl-4-phenylpyrazoles and their medical use |
| EA009919B1 (ru) * | 2003-02-11 | 2008-04-28 | Вернэлис (Кембридж) Лимитед | Соединения изоксазола |
| US20110201587A1 (en) * | 2010-02-16 | 2011-08-18 | Bio Holding, Inc. | Hsp90 inhibitors and methods of use |
-
2004
- 2004-02-09 EA EA200501272A patent/EA009919B1/ru active IP Right Revival
- 2004-02-09 BR BRPI0407403-3A patent/BRPI0407403B1/pt not_active IP Right Cessation
- 2004-02-09 AU AU2004210779A patent/AU2004210779B2/en not_active Expired
- 2004-02-09 PT PT04709273T patent/PT1611112E/pt unknown
- 2004-02-09 DK DK04709273.9T patent/DK1611112T3/da active
- 2004-02-09 WO PCT/GB2004/000506 patent/WO2004072051A1/en not_active Ceased
- 2004-02-09 CN CN2004800093392A patent/CN1771235B/zh not_active Expired - Lifetime
- 2004-02-09 EP EP04709273A patent/EP1611112B1/en not_active Expired - Lifetime
- 2004-02-09 CA CA2515726A patent/CA2515726C/en not_active Expired - Lifetime
- 2004-02-09 MX MXPA05008335A patent/MXPA05008335A/es active IP Right Grant
- 2004-02-09 SI SI200431954T patent/SI1611112T1/sl unknown
- 2004-02-09 KR KR1020057014738A patent/KR101166749B1/ko not_active Expired - Fee Related
- 2004-02-09 JP JP2006502254A patent/JP4921162B2/ja not_active Expired - Lifetime
- 2004-02-09 NZ NZ541479A patent/NZ541479A/en not_active IP Right Cessation
- 2004-02-09 ES ES04709273T patent/ES2393483T3/es not_active Expired - Lifetime
- 2004-02-09 US US10/544,443 patent/US7705027B2/en not_active Expired - Lifetime
-
2005
- 2005-09-09 NO NO20054195A patent/NO335001B1/no unknown
-
2010
- 2010-02-19 US US12/708,686 patent/US8507480B2/en not_active Expired - Fee Related
-
2012
- 2012-06-18 US US13/525,409 patent/US8450310B2/en not_active Expired - Fee Related
- 2012-11-09 CY CY20121101068T patent/CY1113761T1/el unknown
-
2013
- 2013-06-27 US US13/929,098 patent/US9718793B2/en not_active Expired - Fee Related
-
2017
- 2017-06-23 US US15/631,059 patent/US10413550B2/en not_active Expired - Lifetime
-
2019
- 2019-07-31 US US16/528,278 patent/US11234987B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006517572A5 (https=) | ||
| CA2515726A1 (en) | Isoxazole compounds | |
| ES2560627T3 (es) | Compuestos y procedimientos para la inhibición de HDAC | |
| AU2014219283C1 (en) | Benzothiophene derivatives and compositions thereof as selective estrogen receptor degraders | |
| CA2793311C (en) | Modulators of hec1 activity and methods therefor | |
| NZ601408A (en) | Novel 3-hydroxy-5-arylisothiazole derivative | |
| JP2006524673A5 (https=) | ||
| RU2007132262A (ru) | Соединения и композиции в качестве ингибиторов протеинкиназ | |
| JP2009084270A5 (https=) | ||
| RU2009118602A (ru) | Производное индола | |
| KR940013507A (ko) | 아릴 치환 헤테로사이클릭 화합물 | |
| JP2012530765A5 (https=) | ||
| JP2010508296A5 (https=) | ||
| RU2007124545A (ru) | Производные [4-(гетероарил)пиперазин-1-ил]-(2,5-замещенный фенил)метанона в качестве ингибиторов переносчика глицина-1 (glyt-1) для лечения неврологических и психоневрологических заболеваний | |
| CA2427206A1 (en) | Sulfamides as gamma-secretase inhibitors | |
| JP2014530900A5 (https=) | ||
| RU2012132692A (ru) | Новые ингибиторы s-нитрозоглутатионредуктазы | |
| RU2004104951A (ru) | Замещенные пиперазиновые соединения и их применение в качестве ингибиторов окисления жирных кислот | |
| JP2005537323A5 (https=) | ||
| JP2006507247A5 (https=) | ||
| JP2003012668A5 (https=) | ||
| JP2006516626A5 (https=) | ||
| JP2015524483A5 (https=) | ||
| JP2004525183A5 (https=) | ||
| JP2007514639A5 (https=) |